<DOC>
	<DOCNO>NCT00522925</DOCNO>
	<brief_summary>The purpose study see PS433540 lower blood pressure well placebo see safe PS433540 compare placebo .</brief_summary>
	<brief_title>A Trial Evaluate Safety Efficacy PS433540 Treat Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<criteria>Males females 30 80 year Mean seat Systolic Blood Pressure ( SBP ) ≥ 150 ≤ 179 mmHg mean seat DBP &lt; 110 mmHg two consecutive qualify visit . The mean difference SBP two consecutive qualify visit must ≤ 10 mmHg . Mean daytime ( 8AM 4PM ) ambulatory SBP must ≥ 140 ≤ 179 mmHg mean daytime ( 8AM 4PM ) Diastolic Blood Pressure ( DBP ) ≤ 110 mmHg Subjects must usual daytime schedule . Night shift worker exclude participation . Women childbearing potential ( WOCBP ) male subject must use two reliable form contraception sexually active . Alternatively , female subject must postmenopausal ( least 1 year ) Subjects serious disorder may limit ability evaluate efficacy safety PS433540 , include cardiovascular , renal ( include absence one kidney ) , pulmonary , hepatic , gastrointestinal ( include clinically significant malabsorption ) , endocrine/metabolic , hematologic/oncologic ( include active malignancy basal cell carcinoma ) , neurologic psychiatric disease . Subjects history myocardial infarction , angina , coronary angioplasty , bypass surgery New York Heart Association ( NYHA ) class IIIV heart failure within last 6 month . Subjects history cerebrovascular accident transient ischemic attack within last 1 year . Subjects diabetes mellitus ( type I type II ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>hypertension</keyword>
	<keyword>high blood pressure</keyword>
</DOC>